Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02224053 · ClinicalTrials.gov registry record · Phase 1

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

A Phase 1 study of Healthy Volunteer, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
136
Enrollment target
2
Study locations

NCT02224053 is a Phase 1 study of Healthy Volunteer that has completed, run by AstraZeneca. The registered enrollment target is 136 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02224053, a Phase 1 study of Healthy Volunteer, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
136 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers. Volunteers will receive Treatment A (AZD9291 and omeprazole) in Period 1 and Treatment B (AZD9291 only) in Period 2. The dose of AZD9291 in Period 1 and the dose of AZD9291 in Period 2 will be separated by a washout of at least 21 days (the washout will not be more than 5 weeks). The study will be performed at up to 2 sites in the USA and will assess the effect of omeprazole (proton pump inhibitor) on AZD9291 exposure

Conditions Studied

Interventions

  • PROCEDURE Pharmacokinetic sampling - AZD9291
  • DRUG AZD9291 tablet dosing
  • DRUG Omeprazole tablet dosing
  • PROCEDURE Pharmacokinetic sampling - AZ5140 and AZ7550

Study Locations (2)

Kansas

  • Research Site - Overland Park

Minnesota

  • Research Site - Minneapolis

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2014-09
Est. Completion 2015-01
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT02224053

The ClinicalTrials.gov registry entry for NCT02224053 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (32% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 4 interventions - of which Pharmacokinetic sampling - AZD9291 is the first listed.

NCT02224053 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Minnesota.

Frequently Asked Questions

What is clinical trial NCT02224053 about?

NCT02224053 is a clinical study titled "Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers". This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers. Volunteers will receive Treatment A (AZD9291 and omeprazole) in Period 1 and Treatment B (AZD9291 only) in Period 2. The dose of AZ...

What is the current status of trial NCT02224053?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2014-09. Estimated completion is 2015-01.

What conditions does trial NCT02224053 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT02224053?

The interventions under investigation include: Pharmacokinetic sampling - AZD9291 (PROCEDURE), AZD9291 tablet dosing (DRUG), Omeprazole tablet dosing (DRUG), Pharmacokinetic sampling - AZ5140 and AZ7550 (PROCEDURE).

Who is sponsoring clinical trial NCT02224053?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02224053 being conducted?

This trial has 2 study locations across Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.